Navigation

© Zeal News Africa

Weight Loss Jabs Under Fire: Cancer Link, Price Hikes & Post-Use Weight Regain Spark Panic

Published 4 days ago3 minute read
Precious Eseaye
Precious Eseaye
Weight Loss Jabs Under Fire: Cancer Link, Price Hikes & Post-Use Weight Regain Spark Panic

British scientists have unveiled a groundbreaking 'natural Mounjaro' pill, named Elcella, designed to suppress appetite without the severe side effects often associated with conventional slimming injections. Developed by Dr. Madusha Peiris and Dr. Rubina Aktar from Queen Mary University, London, Elcella is made from just three natural oils and is hoped to significantly contribute to solving the global obesity epidemic.

The Elcella capsules, taken twice daily, contain linseed oil (also known as flaxseed), coconut oil, and MCT oil (also derived from coconuts). These ingredients work by triggering the release of natural gut hormones, GLP-1 and peptide YY, which send signals of fullness to the brain. Unlike drugs such as Ozempic, Wegovy, and Mounjaro, which mimic GLP-1 and are notorious for causing nausea, vomiting, diarrhea, and other complications, Elcella stimulates the body's own natural hormone production, leading to no reported side effects in three clinical trials.

A clinical trial of Elcella demonstrated impressive results: patients reduced their calorie intake by 18 percent and lost an average of 1 stone 1 pound (approximately 7 kg) in just 12 weeks. This stands in stark contrast to some synthetic alternatives; for example, patients taking Ozempic reportedly lost just 13 pounds over 40 months. Dr. Peiris explained that while obesity often diminishes one's ability to recognize fullness, Elcella's combination of nutrients effectively reactivates this crucial appetite control mechanism.

A compelling case study is Clare, a 52-year-old healthcare worker from Hertfordshire, who struggled with weight gain exacerbated by medication for a gut condition and Ehlers-Danlos syndrome, which made exercise difficult. Despite rigorous dieting, including consuming only 800 calories a day, she couldn't lose weight. After being accepted onto an Elcella clinical trial in April, Clare experienced a life-changing transformation. Within weeks, her constant hunger stopped, and cravings for carbohydrates diminished. In 12 weeks, she lost over 3 stone (from 13st 10lb to 10st 8lb), 18cm from her waist, and went down two dress sizes. She noted that, unlike her friends on weight-loss jabs, she could still enjoy food and wine without the desire to overeat.

A key innovation in Elcella's design is its specialized enteric coating, developed by co-creator Dr. Aktar. This coating ensures that the pill remains intact through the stomach, delivering its natural ingredients directly to the colon. There, these ingredients hyperactivate the appetite-reducing hormones in the gut, making it more effective than standard supplements that break down prematurely.

Elcella is available online without a prescription, priced at £535.50 for a three-month supply, which equates to approximately £45 per week. Users are advised to take two pills daily for 12 weeks, with no long-term usage limit since it is a supplement that enhances natural bodily processes rather than creating dependency. This offers a significant advantage over prescription-only weight-loss jabs, which are often expensive (Mounjaro is set to rise to £330 per month) and have long waiting lists on the NHS.

Beyond weight loss, patients using Elcella have reported additional benefits, including reduced stomach pain, healthier hair and nails, and more regular bowel movements, suggesting an overall improvement in gut health. This holistic approach to well-being further distinguishes Elcella. The product's creators hope it will empower millions globally to manage their health effectively, free from the concerns of needles or debilitating side effects.

The development of Elcella comes at a critical time, as the UK grapples with high rates of obesity; two in three adults are overweight or obese, contributing to a 39 percent rise in type 2 diabetes among under-40s and linking to at least 13 types of cancer. Elcella presents a promising new option in the fight against this public health challenge.

Loading...
Loading...
Loading...

You may also like...